Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) >= 1%: KEYNOTE-033-MedSci.cn

Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) >= 1%: KEYNOTE-033

Zhou, C; Feng, J; Ma, S; Chen, H; Ma, Z; Huang, C; Zhang, L; He, J; Wang, C; Zhou, J; Danchaivijtr, P; Huang, HC; Vynnychenko, IO; Wang, K; Orlandi, F; Sriuranpong, V; Li, B; Ge, J; Dang, T

ANNALS OF ONCOLOGY, 2020; 31 (): S816

科室
- - 订阅+
  - 更多科室
工具
服务